Skip to main content
SpringerLink
Log in

Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice

  • Review
  • Published:
Journal of Zhejiang University SCIENCE B Aims and scope Submit manuscript

Abstract

Colorectal cancer remains one of the most common types of cancer and leading causes of cancer death worldwide. Although we have made steady progress in chemotherapy and targeted therapy, evidence suggests that the majority of patients undergoing drug therapy experience severe, debilitating, and even lethal adverse drug events which considerably outweigh the benefits. The identification of suitable biomarkers will allow clinicians to deliver the most appropriate drugs to specific patients and spare them ineffective and expensive treatments. Prognostic and predictive biomarkers have been the subjects of many published papers, but few have been widely incorporated into clinical practice. Here, we want to review recent biomarker data related to colorectal cancer, which may have been ready for clinical use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Afzal, S., Jensen, S.A., Vainer, B., Vogel, U., Matsen, J.P., Sørensen, J.B., Andersen, P.K., Poulsen, H.E., 2009. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann. Oncol., 20(10): 1660–1666. [doi:10.1093/annonc/mdp046]

    Article  PubMed  CAS  Google Scholar 

  • Akiyama, Y., Fujita, K., Nagashima, F., Yamamoto, W., Endo, H., Sunakawa, Y., Yamashita, K., Ishida, H., Mizuno, K., Araki, K., et al., 2008. Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy. Ann. Oncol., 19(12):2089–2090. [doi:10.1093/annonc/mdn645]

    Article  PubMed  CAS  Google Scholar 

  • Andreetta, C., Puppin, C., Minisini, A., Valent, F., Pegolo, E., Damante, G., di Loreto, C., Pizzolitto, S., Pandolfi, M., Fasola, G., et al., 2009. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Ann. Oncol., 20(2):265–271. [doi:10.1093/annonc/mdn592]

    Article  PubMed  CAS  Google Scholar 

  • Best, L., Simmonds, P., Baughan, C., Buchanan, R., Davis, C., Fentiman, I., George, S., Gosney, M., Northover, J., Williams, C., 2000. Palliative chemotherapy for advanced or metastatic colorectal cancer. Cochrane Database Syst. Rev., (2):CD001545. [doi:10.1002/14651858.CD001545]

    Google Scholar 

  • Beutler, E., Gelbart, T., Demina, A., 1998. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? PNAS, 95(14):8170–8174.

    Article  PubMed  CAS  Google Scholar 

  • Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J.T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al., 2009. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol., 27(5):663–671. [doi:10.1200/JCO.2008.20.8397]

    Article  PubMed  CAS  Google Scholar 

  • Boland, C.R., Thibodeau, S.N., Hamilton, S.R., Sidransky, D., Eshleman, J.R., Burt, R.W., Meltzer, S.J., Rodriguez-Bigas, M.A., Fodde, R., Ranzani, G.N., et al., 1998. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res., 58(22):5248–5257.

    PubMed  CAS  Google Scholar 

  • Cassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., et al., 2004. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J. Clin. Oncol., 22(11): 2084–2091. [doi:10.1200/JCO.2004.11.069]

    Article  PubMed  CAS  Google Scholar 

  • Chibaudel, B., Tournigand, C., André, T., Larsen, A.K., de Gramont, A., 2010. Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions. Clin. Colorectal Cancer, 9(5):269–273. [doi:10.3816/CCC.2010.n.039]

    Article  PubMed  CAS  Google Scholar 

  • Cohen, V., Panet-Raymond, V., Sabbaghian, N., Morin, I., Batist, G., Rozen, R., 2003. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin. Cancer Res., 9(5):1611–1615.

    PubMed  CAS  Google Scholar 

  • Colucci, G., Gebbia, V., Paoletti, G., Giuliani, F., Caruso, M., Gebbia, N., CartenÌ, G., Agostara, B., Pezzella, G., Manzione, L., et al., 2005. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J. Clin. Oncol., 23(22):4866–4875. [doi:10.1200/JCO.2005.07.113]

    Article  PubMed  CAS  Google Scholar 

  • Coursier, S., Martelet, S., Guillermet, A., Emptoz, J., Villier, C., Bontemps, H., 2010. Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency. Gastroenterol. Clin. Biol., 34(3):218–223. [doi:10.1016/j.gcb.2009.08.014]

    Article  PubMed  CAS  Google Scholar 

  • de Roock, W., Piessevaux, H., de Schutter, J., Janssens, M., de Hertogh, G., Personeni, N., Biesmans, B., van Laethem, J.L., Peeters, M., Humblet, Y., et al., 2008. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol., 19(3): 508–515. [doi:10.1093/annonc/mdm496]

    Article  PubMed  Google Scholar 

  • de Roock, W., Jonker, D.J., di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., et al., 2010a. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA, 304(16):1812–1820. [doi:10.1001/jama.2010.1535]

    Article  PubMed  Google Scholar 

  • de Roock, W., Claes, B., Bernasconi, D., de Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K.T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al., 2010b. Effects of KRAS, BRAF, NRAS, and PIK3A, mutations on the efficacy of cetuximab plus chemotherapy in chemotehrapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol., 11(8):753–762. [doi:10.1016/S1470-2045(10)70130-3]

    Article  PubMed  Google Scholar 

  • Diep, C.B., Thorstensen, L., Meling, G.I., Skovlund, E., Rognum, T.O., Lothe, R.A., 2003. Genetic tumor markers with prognostic impact in Dukes’ stages B and C colorectal cancer patients. J. Clin. Oncol., 21(5):820–829. [doi:10.1200/JCO.2003.05.190]

    Article  PubMed  Google Scholar 

  • Eschrich, S., Yang, I., Bloom, G., Kwong, K.Y., Boulware, D., Cantor, A., Coppola, D., Kruhøffer, M., Aaltonen, L., Orntoft, T.F., et al., 2005. Molecular staging for survival prediction of colorectal cancer patients. J. Clin. Oncol., 23(15):3526–3535. [doi:10.1200/JCO.2005.00.695]

    Article  PubMed  CAS  Google Scholar 

  • Formica, V., Palmirotta, R., del Monte, G., Savonarola, A., Ludovici, G., de Marchis, M.L., Grenga, I., Schirru, M., Guadagni, F., Roselli, M., 2011. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int. J. Colorectal Dis., 26(2):143–151. [doi:10.1007/s00384-0101108-1]

    Article  PubMed  Google Scholar 

  • French, A.J., Sargent, D.J., Burgart, L.J., Foster, N.R., Kabat, B.F., Goldberg, R., Shepherd, L., Windschitl, H.E., Thibodeau, S.N., 2008. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin. Cancer Res., 14(11):3408–3415. [doi:10.1158/1078-0432.CCR-07-1489]

    Article  PubMed  CAS  Google Scholar 

  • Fuchs, C.S., Marshall, J., Mitchell, E., Wierzbicki, R., Ganju, V., Jeffery, M., Schulz, J., Richards, D., Soufi-Mahjoubi, R., Wang, B., et al., 2007. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J. Clin. Oncol., 25(30):4779–4786. [doi:10.1200/JCO.2007.11.3357]

    Article  PubMed  CAS  Google Scholar 

  • Gao, J., Lu, M., Yu, J.W., Li, Y.Y., Shen, L., 2011. Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer, 11:177. [doi:10.1186/1471-2407-11-177]

    Article  PubMed  CAS  Google Scholar 

  • Garman, K.S., Acharya, C.R., Edelman, E., Grade, M., Gaedcke, J., Sud, S., Barry, W., Diehl, A.M., Provenzale, D., Ginsburg, G.S., et al., 2008. A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. PNAS, 105(49): 19432–19437. [doi:10.1073/pnas.0806674105]

    Article  PubMed  CAS  Google Scholar 

  • Gill, S., Loprinzi, C.L., Sargent, D.J., Thomé, S.D., Alberts, S.R., Haller, D.G., Benedetti, J., Francini, G., Shepherd, L.E., Francois, S.J., et al., 2004. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J. Clin. Oncol., 22(10):1797–1806. [doi:10.1200/JCO.2004.09.059]

    Article  PubMed  CAS  Google Scholar 

  • Gray, R., Barnwell, J., McConkey, C., Hills, R.K., Williams, N.S., Kerr, D.J., 2007. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet, 370(9604):2020–2029. [doi:10.1016/S0140-6736(07)61866-2]

    Article  PubMed  Google Scholar 

  • Gray, R.G., Quirke, P., Handley, K., Lopatin, M., Magill, L., Baehner, F.L., Beaumont, C., Clark-Langone, K.M., Yoshizawa, C.N., Lee, M., et al., 2011. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J. Clin. Oncol., 29(35):4611–4619. [doi:10.1200/JCO.2010.32.8732]

    Article  PubMed  Google Scholar 

  • Hoskins, J.M., Goldberg, R.M., Qu, P., Ibrahim, J.G., McLeod, H.L., 2007. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl. Cancer Inst., 99(17):1290–1295. [doi:10.1093/jnci/djm115]

    Article  PubMed  CAS  Google Scholar 

  • Hotta, T., Taniguchi, K., Kobayashi, Y., Johata, K., Sahara, M., Naka, T., Watanabe, T., Ochiai, M., Tanimura, H., Tsubota, Y.T., 2004. Increased expression of thymidine phosphorylase in tumor tissue in proportion to TP-expression in primary normal tissue. Oncol. Rep., 12(3):539–541.

    PubMed  CAS  Google Scholar 

  • Huang, M.Y., Huang, M.L., Chen, M.J., Lu, C.Y., Chen, C.F., Tsai, P.C., Chuang, S.C., Hou, M.F., Lin, S.R., Wang, J.Y., 2011. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet. Genomics, 21(1):18–25. [doi:10.1097/FPC.0b013e3283415124]

    Article  PubMed  CAS  Google Scholar 

  • Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al., 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 350:2335–2342. [doi:10.1056/NEJMoa032691]

    Article  PubMed  CAS  Google Scholar 

  • Hurwitz, H.I., Yi, J., Ince, W., Novotny, W.F., Rosen, O., 2009. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of KRAS mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist, 14(1):22–28. [doi:10.1634/theon cologist.2008-0213]

    Article  PubMed  CAS  Google Scholar 

  • Iacopetta, B., Russo, A., Bazan, V., Dardanoni, G., Gebbia, N., Soussi, T., Kerr, D., Elsaleh, H., Soong, R., Kandioler, D., et al., 2006. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann. Oncol., 17(5):842–847. [doi:10.1093/annonc/mdl035]

    Article  PubMed  CAS  Google Scholar 

  • Inada, M., Sato, M., Morita, S., Kitagawa, K., Kawada, K., Mitsuma, A., Sawaki, M., Fujita, K., Ando, Y., 2010. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int. J. Clin. Pharmacol. Ther., 48(11): 729–734. [doi:10.5414/CPP48729]

    PubMed  CAS  Google Scholar 

  • Innocenti, F., Undevia, S.D., Iyer, L., Chen, P.X., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramírez, J., Rudin, C.M., et al., 2004. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol., 22(8): 1382–1388. [doi:10.1200/JCO.2004.07.173]

    Article  PubMed  CAS  Google Scholar 

  • Innocenti, F., Kroetz, D.L., Schuetz, E., Dolan, M.E., Ramírez, J., Relling, M., Chen, P., Das, S., Rosner, G.L., Ratain, M.J., 2009. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol., 27(16):2604–2614. [doi:10.1200/JCO.2008.20.6300]

    Article  PubMed  CAS  Google Scholar 

  • Jada, S.R., Lim, R., Wong, C.I., Shu, X., Lee, S.C., Zhou, Q., Goh, B.C., Chowbay, B., 2007. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan induced neutropenia in Asian cancer patients. Cancer Sci., 98(9):1461–1467. [doi:10.1111/j.1349-7006.2007.00541.x]

    Article  PubMed  CAS  Google Scholar 

  • Jakobsen, A., Nielsen, J.N., Gyldenkerne, N., Lindeberg, J., 2005. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J. Clin. Oncol., 23(7):1365–1369. [doi:10.1200/JCO.2005.06.219]

    Article  PubMed  CAS  Google Scholar 

  • Jorissen, R.N., Gibbs, P., Christie, M., Prakash, S., Lipton, L., Desai, J., Kerr, D., Aaltonen, L.A., Arango, D., Kruhøffer, M., et al., 2009. Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer. Clin. Cancer Res., 15(24):7642–7651. [doi:10.1158/1078-0432.CCR-09-1431]

    Article  PubMed  CAS  Google Scholar 

  • Kalow, W., Tang, B., Endrenyi, L., 1998. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics, 8(4):283–289.

    Article  PubMed  CAS  Google Scholar 

  • Kaniwa, N., Kurose, K., Jinno, H., Tanaka-Kagawa, T., Saito, Y., Saeki, M., Sawada, J., Tohkin, M., Hasegawa, R., 2005. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (P229L) found in an African-American. Drug Metab. Dispos., 33(3):458–465. [doi:10.1124/dmd.104.001800]

    Article  PubMed  CAS  Google Scholar 

  • Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., O’Callaghan, C.J., Tu, D., Tebbutt, N.C., Simes, R.J., Chalchal, H., Shapiro, J.D., Robitaille, S., et al., 2008. KRAS mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med., 359(17):1757–1765. [doi:10.1056/NEJMoa0804385]

    Article  PubMed  CAS  Google Scholar 

  • Kawakami, K., Omura, K., Kanehira, E., Watanabe, Y., 1999. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res., 19(4B): 3249–3252.

    PubMed  CAS  Google Scholar 

  • Khambata-Ford, S., Garrett, C.R., Meropol, N.J., Basik, M., Harbison, C.T., Wu, S., Wong, T.W., Huang, X., Takimoto, C.H., Godwin, A.K., et al., 2007. Expression of epiregulin and amphiregulin and KRAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol., 25(22): 3230–3237. [doi:10.1200/JCO.2006.10.5437]

    Article  PubMed  CAS  Google Scholar 

  • Köhne, C.H., Lenz, H.J., 2009. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist, 14(5):478–488. [doi:10.1634/theoncologist.2008-0202]

    Article  PubMed  Google Scholar 

  • Lamas, M.J., Duran, G., Balboa, E., Bernardez, B., Touris, M., Vidal, Y., Gallardo, E., Lopez, R., Carracedo, A., Barros, F., 2011. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics, 12(3):433–442. [doi:10.2217/pgs.10.196]

    Article  PubMed  CAS  Google Scholar 

  • Lecomte, T., Landi, B., Beaune, P., Laurent-Puig, P., Loriot, M.A., 2006. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin. Cancer Res., 12(10):3050–3056. [doi:10.1158/1078-0432.CCR05-2076]

    Article  PubMed  CAS  Google Scholar 

  • Lièvre, A., Bachet, J.B., le Corre, D., Boige, V., Landi, B., Emile, J.F., Côté, J.F., Tomasic, G., Penna, C., Ducreux, M., et al., 2006. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res., 66(8):3992–3995. [doi:10.1158/0008-5472.CAN-06-0191]

    Article  PubMed  Google Scholar 

  • Marsh, S., McLeod, H., 2001. Thymidylate synthase pharmacogenetics in colorectal cancer. Clin. Colorectal. Cancer, 1(3):175–178. [doi:10.3816/CCC.2001.n.018]

    Article  PubMed  CAS  Google Scholar 

  • Mattison, L.K., Soong, R., Diasio, R.B., 2002. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics, 3(4):485–492. [doi:10.1517/14622416.3.4.485]

    Article  PubMed  CAS  Google Scholar 

  • Mayer, A., Takimoto, M., Fritz, E., Schellander, G., Kofler, K., Ludwig, H., 1993. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer, 71(8):2454–2460.

    Article  PubMed  CAS  Google Scholar 

  • Mcleod, H.L., Sargent, D.J., Marsh, S., Green, E.M., King, C.R., Fuchs, C.S., Ramanathan, R.K., Williamson, S.K., Findlay, B.P., Thibodeau, S.N., et al., 2010. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J. Clin. Oncol., 28(20):3227–3233. [doi:10.1200/JCO.2009.21.7943]

    Article  PubMed  CAS  Google Scholar 

  • Milano, G., Etienne, M.C., Pierrefite, V., Barberi-Heyob, M., Deporte-Fety, R., Renée, N., 1999. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br. J. Cancer, 79:627–630. [doi:10.1038/sj.bjc.6690098]

    Article  PubMed  CAS  Google Scholar 

  • Moreno, V., Gemignani, F., Landi, S., Gioia-Patricola, L., Chabrier, A., Blanco, I., González, S., Guino, E., Capellà, G., Canzian, F., 2006. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin. Cancer Res., 12(7Pt1): 2101–2108. [doi:10.1158/1078-0432.CCR-05-1363]

    Article  PubMed  CAS  Google Scholar 

  • Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., di Nicolantonio, F., Gambacorta, M., Siena, S., Bardelli, A., 2005. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol., 6(5):279–286. [doi:10.1016/S1470-2045(05)70102-9]

    Article  PubMed  CAS  Google Scholar 

  • Moroni, M., Sartore-Bianchi, A., Veronese, S., Siena, S., 2008. EGFR FISH in colorectal cancer: what is the current reality? Lancet Oncol., 9(5):402–403. [doi:10.1016/S1470-2045(08)70109-8]

    Article  PubMed  Google Scholar 

  • O’Connell, M.J., Lavery, I., Yothers, G., Paik, S., Clark-Langone, K.M., Lopatin, M., Watson, D., Baehner, F.L., Shak, S., Baker, J., et al., 2010. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J. Clin. Oncol., 28: 3937–3944. [doi:10.1200/JCO.2010.28.9538]

    Article  PubMed  Google Scholar 

  • Palomaki, G.E., Bradley, L.A., Douglas, M.P., Kolor, K., Dotson, W.D., 2009. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet. Med., 11(1):21–34. [doi:10.1097/GIM.0b013e31818efd77]

    Article  PubMed  CAS  Google Scholar 

  • Petrioli, R., Bargagli, G., Lazzi, S., Pascucci, A., Francini, E., Bellan, C., Conca, R., Martellucci, I., Fiaschi, A.I., Lorenzi, B., et al., 2010. Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin. Anticancer Drugs, 21(3):313–319. [doi:10.1097/CAD.0b013e328334d88a]

    Article  PubMed  CAS  Google Scholar 

  • Popat, S., Hubner, R., Houlston, R.S., 2005. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol., 23(3):609–618. [doi:10.1200/JCO.2005.01.086]

    Article  PubMed  CAS  Google Scholar 

  • Raida, M., Schwabe, W., Hausler, P., van Kuilenburg, A.B., van Gennip, A.H., Behnke, D., Höffken, K., 2001. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin. Cancer Res., 7(9):2832–2839.

    PubMed  CAS  Google Scholar 

  • Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K.W., Vogelstein, B., Velculescu, V.E., 2002. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature, 418(6901):934. [doi:10.1038/418934a]

    Article  PubMed  CAS  Google Scholar 

  • Ribic, C.M., Sargent, D.J., Moore, M.J., Thibodeau, S.N., French, A.J., Goldberg, R.M., Hamilton, S.R., Laurent-Puig, P., Gryfe, R., Shepherd, L.E., et al., 2003. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med., 349(3):247–257. [doi:10.1056/NEJMoa022289]

    Article  PubMed  CAS  Google Scholar 

  • Roth, A.D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al., 2010. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol., 28(3):466–474. [doi:10.1200/JCO.2009.23.3452]

    Article  PubMed  CAS  Google Scholar 

  • Sartore-Bianchi, A., Moroni, M., Veronese, S., Carnaghi, C., Bajetta, E., Luppi, G., Sobrero, A., Barone, C., Cascinu, S., Colucci, G., et al., 2007. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J. Clin. Oncol., 25(22):3238–3245. [doi:10.1200/JCO.2007.11.5956]

    Article  PubMed  CAS  Google Scholar 

  • Scaltriti, M., Baselga, J., 2006. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res., 12(18):5268–5272. [doi:10.1158/1078-0432.CCR-05-1554]

    Article  PubMed  CAS  Google Scholar 

  • Scartozzi, M., Galizia, E., Chiorrini, S., Giampieri, R., Berardi, R., Pierantoni, C., Cascinu, S., 2009. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann. Oncol., 20(2):227–230. [doi:10.1093/annonc/mdn637]

    Article  PubMed  CAS  Google Scholar 

  • Schneider, B.P., Wang, M., Radovich, M., Sledge, G.W., Badve, S., Thor, A., Flockhart, D.A., Hancock, B., Davidson, N., Gralow, J., et al., 2008. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol., 26(28):4672–4678. [doi:10.1200/JCO.2008.16.1612]

    Article  PubMed  CAS  Google Scholar 

  • Schultheis, A.M., Lurje, G., Rhodes, K.E., Zhang, W., Yang, D., Garcia, A.A., Morgan, R., Gandara, D., Scudder, S., Oza, A., et al., 2008. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin. Cancer Res., 14(22):7554–7563. [doi:10.1158/1078-0432.CCR-08-0351]

    Article  PubMed  CAS  Google Scholar 

  • Seck, K., Riemer, S., Kates, R., Ullrich, T., Lutz, V., Harbeck, N., Schmitt, M., Kiechle, M., Diasio, R., Gross, E., 2005. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin. Cancer Res., 11(16):5886–5892. [doi:10.1158/1078-0432.CCR-04-1784]

    Article  PubMed  CAS  Google Scholar 

  • Segaert, S., Chiritescu, G., Lemmens, L., Dumon, K., van Cutsem, E., Tejpar, S., 2009. Skin toxicities of targeted therapies. Eur. J. Cancer, 45(Suppl. 1):295–308. [doi:10.1016/S0959-8049(09)70044-9]

    Article  PubMed  Google Scholar 

  • Siegel, R., Ward, E., Brawley, O., Jemal, A., 2011. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin., 61(4):212–236. [doi:10.3322/caac.20121]

    Article  PubMed  Google Scholar 

  • Siena, S., Sartore-Bianchi, A., di Nicolantonio, F., Balfour, J., Bardelli, A., 2009. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl. Cancer Inst., 101(19):1308–1324. [doi:10.1093/jnci/djp280]

    Article  PubMed  CAS  Google Scholar 

  • Sinicrope, F.A., Foster, N.R., Thibodeau, S.N., Marsoni, S., Monges, G., Labianca, R., Yothers, G., Allegra, C., Moore, M.J., Gallinger, S., et al., 2011. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J. Natl. Cancer Inst., 103(11):863–875. [doi:10.1093/jnci/djr153]

    Article  PubMed  CAS  Google Scholar 

  • Spano, J.P., Fagard, R., Soria, J.C., Rixe, O., Khayat, D., Milano, G., 2005. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann. Oncol., 16(2):189–194. [doi:10.1093/annonc/mdi057]

    Article  PubMed  CAS  Google Scholar 

  • Stockmann, C., Doedens, A., Weidemann, A., Zhang, N., Takeda, N., Greenberg, J.I., Cheresh, D.A., Johnson, R.S., 2008. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature, 456: 814–818. [doi:10.1038/nature07445]

    Article  PubMed  CAS  Google Scholar 

  • Sugatani, J., Yamakawa, K., Yoshinari, K., Machida, T., Takagi, H., Mori, M., Kakizaki, S., Sueyoshi, T., Negishi, M., Miwa, M., 2002. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem. Biophys. Res. Commun., 292(2): 492–497. [doi:10.1006/bbrc.2002.6683]

    Article  PubMed  CAS  Google Scholar 

  • Suh, K.W., Kim, J.H., Kim, D.Y., Kim, Y.B., Lee, C., Choi, S., 2006. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann. Surg. Oncol., 13(11):1379–1385. [doi:10.1245/s10434-006-9112-y]

    Article  PubMed  Google Scholar 

  • van Kuilenburg, A.B., Meinsma, R., Zoetekouw, L., van Gennip, A.H., 2002. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1G>A mutation. Int. J. Cancer, 101(3):253–258. [doi:10.1002/ijc.10599]

    Article  PubMed  Google Scholar 

  • Villafranca, E., Okruzhnov, Y., Dominguez, M.A., García-Foncillas, J., Azinovic, I., Martínez, E., Illarramendi, J.J., Arias, F., Martínez Monge, R., Salgado, E., et al., 2001. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol., 19(6): 1779–1786.

    PubMed  CAS  Google Scholar 

  • Walther, A., Johnstone, E., Swanton, C., Midgley, R., Tomlinson, I., Kerr, D., 2009. Genetic prognostic and predictive markers in colorectal cancer. Nat. Rev. Cancer, 9(7):489–499. [doi:10.1038/nrc2645]

    Article  PubMed  CAS  Google Scholar 

  • Wang, T.L., Diaz, L.A.Jr., Romans, K., Bardelli, A., Saha, S., Galizia, G., Choti, M., Donehower, R., Parmigiani, G., Shih, I.M., et al., 2004. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. PNAS, 101(9):3089–3094. [doi:10.1073/pnas.0308716101]

    Article  PubMed  CAS  Google Scholar 

  • Wang, Y., Jatkoe, T., Zhang, Y., Mutch, M.G., Talantov, D., Jiang, J., McLeod, H.L., Atkins, D., 2004. Gene expression profiles and molecular markers to predict recurrence of Dukes’ B colon cancer. J. Clin. Oncol., 22(9): 1564–1571. [doi:10.1200/JCO.2004.08.186]

    Article  PubMed  CAS  Google Scholar 

  • Watson, R.G., McLeod, H.L., 2011. Pharmacogenomic contribution to drug response. Cancer J., 17(2):80–88. [doi:10.1097/PPO.0b013e3182147432]

    Article  PubMed  CAS  Google Scholar 

  • Weaver, D.A., Crawford, E.L., Warner, K.A., Elkhairi, F., Khuder, S.A., Willey, J.C., 2005. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol. Cancer, 4(1):18. [doi:10.1186/14764598-4-18]

    Article  PubMed  Google Scholar 

  • Wei, X., McLeod, H.L., McMurrough, J., Gonzalez, F.J., Fernandez-Salguero, P., 1996. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest., 98(3):610–615. [doi:10.1172/JCI118830]

    Article  PubMed  CAS  Google Scholar 

  • Weisberg, I., Tran, P., Christensen, B., Sibani, S., Rozen, R., 1998. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol. Genet. Metab., 64(3): 169–172. [doi:10.1006/mgme.1998.2714]

    Article  PubMed  CAS  Google Scholar 

  • Weitz, J., Koch, M., Debus, J., Höhler, T., Galle, P.R., Büchler, M.W., 2005. Colorectal cancer. Lancet, 365(9454): 153–165. [doi:10.1016/S0140-6736(05)17706-X]

    Article  PubMed  Google Scholar 

  • Yin, M., Yan, J., Martinez-Balibrea, E., Graziano, F., Lenz, H.J., Kim, H.J., Robert, J., Im, S.A., Wang, W.S., Etienne-Grimaldi, M.C., et al., 2011. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin. Cancer Res., 17(6):1632–1640. [doi:10.1158/1078-0432.CCR-10-2169]

    Article  PubMed  CAS  Google Scholar 

  • Zhang, W., Press, O.A., Haiman, C.A., Yang, D.Y., Gordon, M.A., Fazzone, W., El-Khoueiry, A., Iqbal, S., Sherrod, A.E., Lurje, G., et al., 2007. Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. J. Clin. Oncol., 25(24):3726–3731. [doi:10.1200/JCO.2007.11.4710]

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China

    Wei-qin Jiang, Wei-bin Wang, Hao-hao Wang, Hai-ping Jiang & Li-song Teng

  2. Institute of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China

    Fang-fang Fu & Yang-xia Li

Authors
  1. Wei-qin Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fang-fang Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yang-xia Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei-bin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hao-hao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hai-ping Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Li-song Teng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li-song Teng.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jiang, Wq., Fu, Ff., Li, Yx. et al. Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice. J. Zhejiang Univ. Sci. B 13, 663–675 (2012). https://doi.org/10.1631/jzus.B1100340

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1631/jzus.B1100340

Key words

CLC number

Search

Navigation